Acer Therapeutics Inc.
| NASDAQ: ACER | Healthcare / Biotechnology / USA |
| 0.8044 | -0.0259 | -3.12% | Vol 125.79K | 1Y Perf -38.95% |
| Sep 22nd, 2023 16:00 DELAYED |
| BID | 0.8010 | ASK | 0.8200 | ||
| Open | 0.8111 | Previous Close | 0.8303 | ||
| Pre-Market | - | After-Market | 0.80 | ||
| - - | 0.00 -0.55% |
| Target Price | 11.00 | Analyst Rating | Moderate Buy 2.33 | |
| Potential % | 1.27K | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | ★ 38.80 | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 6.31 | Earnings Rating | Strong Buy | |
| Market Cap | 19.68M | Earnings Date | 13th Nov 2023 | |
| Alpha | -0.02 | Standard Deviation | 0.25 | |
| Beta | 0.44 |
Today's Price Range 0.80340.8390 | 52W Range 0.55154.56 | 5 Year PE Ratio Range -4.00-1.90 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -6.92% | ||
| 1 Month | 23.72% | ||
| 3 Months | -8.59% | ||
| 6 Months | 4.20% | ||
| 1 Year | -38.95% | ||
| 3 Years | -67.30% | ||
| 5 Years | -97.40% | ||
| 10 Years | -99.46% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -71.77 | |||
ROE last 12 Months | 410.14 | |||
ROA (5Y Avg) | -35.24 | |||
ROA last 12 Months | -99.18 | |||
ROC (5Y Avg) | -230.95 | |||
ROC last 12 Months | -147.90 | |||
Return on invested Capital Q | -719.67 | |||
Return on invested Capital Y | -719.67 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.80 | ||||
| 16.46 | ||||
| 201.62 | ||||
| 31.40 | ||||
| -2.50 | ||||
| -1.43 | ||||
| -2.77 | ||||
| -0.62 | ||||
| 56.83M | ||||
| Forward PE | 7.20 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.30 | ||||
| 0.40 | ||||
| 0.01 | ||||
| 0.04 | ||||
| -4 429.70 | ||||
| Leverage Ratio | -2.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -6 603.00 | ||||
| -6 582.90 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.26 | -0.23 | 11.54 |
| Q01 2023 | -0.29 | 1.08 | 472.41 |
| Q04 2022 | -0.35 | -0.32 | 8.57 |
| Q03 2022 | -0.76 | -0.31 | 59.21 |
| Q02 2022 | -0.58 | -0.48 | 17.24 |
| Q01 2022 | -0.18 | -0.49 | -172.22 |
| Q04 2021 | -0.08 | -0.31 | -287.50 |
| Q03 2021 | -0.28 | -0.23 | 17.86 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.13 | 35.00 | Positive |
| 12/2023 QR | -0.08 | 20.00 | Positive |
| 12/2023 FY | -0.32 | 38.46 | Positive |
| 12/2024 FY | 0.12 | 0.00 | - |
| Next Report Date | 13th Nov 2023 |
| Estimated EPS Next Report | -0.13 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 125.79K |
| Shares Outstanding | 24.46K |
| Shares Float | 19.96M |
| Trades Count | 552 |
| Dollar Volume | 102.82K |
| Avg. Volume | 3.03M |
| Avg. Weekly Volume | 221.55K |
| Avg. Monthly Volume | 6.55M |
| Avg. Quarterly Volume | 2.32M |
Acer Therapeutics Inc. (NASDAQ: ACER) stock closed at 0.8044 per share at the end of the most recent trading day (a -3.12% change compared to the prior day closing price) with a volume of 125.79K shares and market capitalization of 19.68M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 18 people. Acer Therapeutics Inc. CEO is Chris Schelling.
The one-year performance of Acer Therapeutics Inc. stock is -38.95%, while year-to-date (YTD) performance is -67.95%. ACER stock has a five-year performance of -97.4%. Its 52-week range is between 0.5515 and 4.56, which gives ACER stock a 52-week price range ratio of 6.31%
Acer Therapeutics Inc. currently has a PE ratio of -1.80, a price-to-book (PB) ratio of 16.46, a price-to-sale (PS) ratio of 201.62, a price to cashflow ratio of 31.40, a PEG ratio of -, a ROA of -99.18%, a ROC of -147.90% and a ROE of 410.14%. The company’s profit margin is -%, its EBITDA margin is -6 582.90%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Acer Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.13 for the next earnings report. Acer Therapeutics Inc.’s next earnings report date is 13th Nov 2023.
The consensus rating of Wall Street analysts for Acer Therapeutics Inc. is Moderate Buy (2.33), with a target price of $11, which is +1 267.48% compared to the current price. The earnings rating for Acer Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Acer Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Acer Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.98, ATR14 : 0.10, CCI20 : -22.47, Chaikin Money Flow : -0.12, MACD : 0.01, Money Flow Index : 22.58, ROC : -7.47, RSI : 47.81, STOCH (14,3) : 1.63, STOCH RSI : 0.00, UO : 46.88, Williams %R : -98.37), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Acer Therapeutics Inc. in the last 12-months were: Chris Schelling (Buy at a value of $1 000 000), Stephen Aselage (Buy at a value of $500 000)
Acer Therapeutics Inc.
Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.
CEO: Chris Schelling
Telephone: +1 844 902-6100
Address: 300 Washington Street, Newton 02458, MA, US
Number of employees: 18
TipRanks News for ACER
Thu, 31 Aug 2023 11:37 GMT Zevra Therapeutics to acquire Acer Therapeutics in potential $91M transaction
- TipRanks. All rights reserved.
